Latest News - AMD

Friday, January 05, 2018 | Clinical Trials, AMD

Ohr Pharmaceutical Misses Primary Efficacy Endpoint in Wet-AMD Study

Ohr Pharmaceutical reported topline data from the MAKO study, which did not meet its primary efficacy endpoint. The MAKO study evaluated the efficacy and safety of topically administered squalamine in…

Read the full story

Wednesday, November 08, 2017 | Clinical Trials, AMD

LumiThera Unveils LIGHTSITE 1 Dry AMD Clinical Interim Data

LumiThera announced topline interim results from the LIGHTSITE 1 trial for treatment of dry age-related macular degeneration (AMD) trial utilizing its LT-300 device. The 30-subject pilot study funded …

Read the full story

Thursday, October 19, 2017 | Clinical Trials, Retina, AMD, Genentech

Genentech Completes Patient Enrollment In Phase 2 Study Evaluating A New Delivery System for Lucentis

Genentech has completed enrollment in the LADDER (Long Acting Delivery of Ranibizumab) trial, a phase 2, multicenter, randomized, active treatment-controlled clinical trial investigatin…

Read the full story

Thursday, October 19, 2017 | Acquisitions/Mergers, Blindness, AMD, Pixium Vision

Pixium Vision Receives Approval for First-in-Human Clinical Trial of PRIMA, Its Miniaturized Sub-Retinal Implant

Pixium Vision announced that its next-generation miniaturized wireless subretinal implant, PRIMA, aimed at restoring vision in patients affected by retinal dystrophies, received authorization from the…

Read the full story

Friday, October 06, 2017 | Earnings & Financials, Retina, AMD

PanOptica Secures Funding to Advance Clinical Development of PAN-9080 Topical Anti-VEGF Eye Drop

PanOptica announced that it has secured $11 million in a Series B financing to enable clinical advancement of PAN-90806, a small molecule anti-vascular endothelial growth factor (anti-VEGF) eye drop f…

Read the full story

Thursday, October 05, 2017 | Acquisitions/Mergers, Retina, Aerie Pharmaceuticals, AMD

Aerie Pharmaceuticals Announces Drug Delivery Asset Acquisition to Advance Its Retinal Disease Program

Aerie Pharmaceuticals announced that it has acquired rights to use Envisia Therapeutics' PRINT technology in ophthalmology and certain other assets. The PRINT technology is a proprietary system ca…

Read the full story

Tuesday, September 19, 2017 | Clinical Trials, Retina, AMD, GrayBug

Graybug Vision Initiates Phase 1/2 Trial of GB-102 for Wet AMD

Graybug Vision announced that it has begun dosing patients with wet AMD in its first clinical trial of GB-102, its lead product. GB-102 is a novel intravitreal (IVT) injectable depot formulation of su…

Read the full story

Monday, September 11, 2017 | Clinical Trials, Retina, AMD, Genentech

Genentech's Lampalizumab Fails Phase 3 Study for Geographic Atrophy

Genentech announced that the primary endpoint has not been met in Spectri, the first of two phase 3 studies evaluating the safety and efficacy of lampalizumab, an investigational medicine for the trea…

Read the full story

Thursday, August 24, 2017 | Clinical Trials, Retina, AMD

Apellis Pharmaceuticals Announces APL-2 Met its Primary Endpoint in a Phase 2 Study in Patients with Geographic Atrophy

Apellis Pharmaceuticals announced that its complement C3 inhibitor, APL-2, met its primary endpoint in a phase 2 clinical trial (FILLY) in patients with geographic atrophy (GA) associated with age-rel…

Read the full story

Wednesday, August 16, 2017 | Retina, AMD, Opthea

New Anti-VEGF Drug Promising for Wet Macular Degeneration

A new antivascular endothelial growth-factor (VEGF) drug, OPT-302 (Opthea), appears to be safe and shows signs of effectiveness in the treatment of neovascular age-related macular degeneration, new re…

Read the full story

Monday, August 14, 2017 | Retina, AMD, BioTime

BioTime Announces $2 Million Grant for Further Development of OpRegen for Dry AMD

BioTime has been awarded a new grant for 2017 of up to 7.2 million Israeli New Shekels (approximately $2 million) from the Israel Innovation Authority (IIA) to fund the continued development of OpRege…

Read the full story

Monday, August 14, 2017 | Clinical Trials, Retina, AMD, Ophthotech

Ophthotech's Fovista Fails Third Phase 3 Trial in Wet AMD

Ophthotech announced that the prespecified primary endpoint of mean change in visual acuity at 12 months was not achieved in its phase 3 clinical trial investigating the superiority of Fovis…

Read the full story

Monday, July 31, 2017 | Partnerships, Akorn Pharmaceuticals, AMD

Aerie Pharmaceuticals Enters into Collaboration with DSM Focused on Technology to Potentially Deliver Aerie Compounds to Treat Retinal Diseases

Aerie Pharmaceuticals announced that it has entered into a collaborative research, development, and license agreement with DSM. The research collaboration agreement includes an option to license DSM&r…

Read the full story

Friday, July 28, 2017 | Retina, AMD

NEI 3-D Retina Organoid Challenge (3-D ROC)

The National Eye Institute (NEI), part of the National Institutes of Health, is seeking ideas for how to develop advances in vitro 3-D human retina organoid models. The goal of the challenge is to tur…

Read the full story

Wednesday, July 26, 2017 | Clinical Trials, Earnings & Financials, AMD, Ophthotech

Ophthotech Expands Focus with Development for Ophthalmic Orphan Diseases

Ophthotech announced that the company is pursuing a strategy to leverage its clinical experience and retina expertise to identify and develop therapies to treat multiple orphan ophthalmic diseases for…

Read the full story
Load More